Qianqian Ellie Cheng1, Graham E Quinn2, Ebenezer Daniel3, Agnieshka Baumritter4, Eli Smith3, Gui-Shuang Ying5. 1. College of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania; Division of Pediatric Ophthalmology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania. 4. Division of Pediatric Ophthalmology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: gsying@pennmedicine.upenn.edu.
Abstract
PURPOSE: To determine the incidence of and timing and predictors for progression from pre-plus to plus disease, based on evaluation of images. METHODS: Two trained readers independently evaluated posterior pole images of infants from 13 North American centers for pre-plus/plus disease, stage, and zone of retinopathy of prematurity (ROP). Discrepancies between readers were adjudicated. To be eligible for analysis, eyes had to have at least two imaging sessions, the earlier one with pre-plus disease. RESULTS: Of 681 eyes of 444 infants with pre-plus first detected at mean postmenstrual age (PMA) of 35.5 ± 2.1 weeks, 54 (7.9%) progressed to plus disease at a mean PMA of 37.6 ± 2.4 weeks with the mean interval for progression of 2.7 weeks (range, 0.4-8.9 weeks). Progression rate was higher for eyes with larger number of quadrants of pre-plus (44% for eyes with four quadrants vs 4% with one quadrant [P < 0.0001]), earlier PMA with pre-plus (18% for 32 weeks' PMA vs 3% for PMA of >37 weeks [P = 0.02]), higher ROP stage (12% for stage 3, 2.5% for no ROP [P < 0.0001]), lower ROP zone (24% for zone I, 6% for zone II or no ROP [P < 0.0001]) at the time of first pre-plus detection. CONCLUSIONS: Based on image evaluation, 8% of eyes progressed from pre-plus to plus disease at a mean interval of 3 weeks. Pre-plus in multiple quadrants, higher stages of ROP, and lower zones of ROP were associated with higher risk of progression. Image evaluation for pre-plus may help in the identification of high-risk eyes for developing plus disease.
PURPOSE: To determine the incidence of and timing and predictors for progression from pre-plus to plus disease, based on evaluation of images. METHODS: Two trained readers independently evaluated posterior pole images of infants from 13 North American centers for pre-plus/plus disease, stage, and zone of retinopathy of prematurity (ROP). Discrepancies between readers were adjudicated. To be eligible for analysis, eyes had to have at least two imaging sessions, the earlier one with pre-plus disease. RESULTS: Of 681 eyes of 444 infants with pre-plus first detected at mean postmenstrual age (PMA) of 35.5 ± 2.1 weeks, 54 (7.9%) progressed to plus disease at a mean PMA of 37.6 ± 2.4 weeks with the mean interval for progression of 2.7 weeks (range, 0.4-8.9 weeks). Progression rate was higher for eyes with larger number of quadrants of pre-plus (44% for eyes with four quadrants vs 4% with one quadrant [P < 0.0001]), earlier PMA with pre-plus (18% for 32 weeks' PMA vs 3% for PMA of >37 weeks [P = 0.02]), higher ROP stage (12% for stage 3, 2.5% for no ROP [P < 0.0001]), lower ROP zone (24% for zone I, 6% for zone II or no ROP [P < 0.0001]) at the time of first pre-plus detection. CONCLUSIONS: Based on image evaluation, 8% of eyes progressed from pre-plus to plus disease at a mean interval of 3 weeks. Pre-plus in multiple quadrants, higher stages of ROP, and lower zones of ROP were associated with higher risk of progression. Image evaluation for pre-plus may help in the identification of high-risk eyes for developing plus disease.
Authors: Devon H Ghodasra; Karen A Karp; Gui-Shuang Ying; Monte D Mills; Clare Wilson; Alistair R Fielder; Jeffery Ng; Graham E Quinn Journal: Arch Ophthalmol Date: 2010-06
Authors: Ebenezer Daniel; Graham E Quinn; P Lloyd Hildebrand; Anna Ells; G Baker Hubbard; Antonio Capone; E Revell Martin; Candace P Ostroff; Eli Smith; Maxwell Pistilli; Gui-Shuang Ying Journal: JAMA Ophthalmol Date: 2015-06 Impact factor: 7.389
Authors: Gui-Shuang Ying; Graham E Quinn; Kelly C Wade; Michael X Repka; Agnieshka Baumritter; Ebenezer Daniel Journal: JAMA Ophthalmol Date: 2015-03 Impact factor: 7.389